Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Daniel K. Spiegelman net worth and biography

Daniel Spiegelman Biography and Net Worth

Director of Myriad Genetics

Daniel K. Spiegelman has been a Director of the company since May 2020. Most recently, he served as Executive Vice President and Chief Financial Officer at BioMarin Pharmaceuticals, Inc. Prior to that, he held several roles, including Senior Vice President and Chief Financial Officer of CV Therapeutics and Treasurer at Genentech, Inc. He is currently a member of the board of directors at Tizona Therapeutics, Inc., a private pharmaceutical company. Mr. Spiegelman received a B.A. degree from Stanford University and a M.B.A. from the Stanford Graduate School of Business.

What is Daniel K. Spiegelman's net worth?: The estimated net worth of Daniel K. Spiegelman is at least $749,525.43 as of June 2nd, 2023. Mr. Spiegelman owns 40,493 shares of Myriad Genetics stock worth more than $749,525 as of April 19th. This net worth evaluation does not reflect any other assets that Mr. Spiegelman may own. Learn More about Daniel K. Spiegelman's net worth.
How do I contact Daniel K. Spiegelman?: The corporate mailing address for Mr. Spiegelman and other Myriad Genetics executives is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. Myriad Genetics can also be reached via phone at (801) 584-3600 and via email at [email protected]. Learn More on Daniel K. Spiegelman's contact information.
Has Daniel K. Spiegelman been buying or selling shares of Myriad Genetics?: Daniel K. Spiegelman has not been actively trading shares of Myriad Genetics during the past quarter. Most recently, Daniel K. Spiegelman sold 8,638 shares of the business's stock in a transaction on Friday, June 2nd. The shares were sold at an average price of $23.01, for a transaction totalling $198,760.38. Following the completion of the sale, the director now directly owns 40,493 shares of the company's stock, valued at $931,743.93. Learn More on Daniel K. Spiegelman's trading history.
Who are Myriad Genetics' active insiders?: Myriad Genetics' insider roster includes Jayne Hart (Insider), Nicole Lambert (Insider), Jerry Lanchbury (Insider), Dennis Langer (Director), S. Phanstiel (Director), Richard Riggsbee (CFO), and Daniel Spiegelman (Director). Learn More on Myriad Genetics' active insiders.
Are insiders buying or selling shares of Myriad Genetics?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 38,638 shares worth more than $669,460.38. The most recent insider tranaction occured on November, 1st when CFO Richard Bryan Riggsbee sold 30,000 shares worth more than $470,700.00. Insiders at Myriad Genetics own 2.0% of the company. Learn More about insider trades at Myriad Genetics.
Information on this page was last updated on 11/1/2023.

Daniel K. Spiegelman Insider Trading History at Myriad Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/2/2023	Sell	8,638	$23.01	$198,760.38	40,493
6/6/2022	Sell	6,424	$19.25	$123,662.00	33,980
6/17/2021	Sell	3,139	$30.52	$95,802.28	23,129
5/28/2021	Sell	7,142	$28.99	$207,046.58	13,420

Daniel K. Spiegelman Buying and Selling Activity at Myriad Genetics

Myriad Genetics Company Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $18.50

$18.25

$18.69

50 Day Range

MA: $21.61

$18.51

$23.59

2 Week Range

Now: $18.50

$13.82

$24.21

Volume

487,827 shs

Average Volume

626,910 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95